Elo Mutual Pension Insurance Co Increases Holdings in Bristol-Myers Squibb (NYSE:BMY)
Elo Mutual Pension Insurance Co Increases Holdings in Bristol-Myers Squibb (NYSE:BMY)
Elo Mutual Pension Insurance Co boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 4.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 174,571 shares of the biopharmaceutical company's stock after purchasing an additional 8,030 shares during the period. Elo Mutual Pension Insurance Co's holdings in Bristol-Myers Squibb were worth $12,749,000 at the end of the most recent reporting period.
根據百時美施貴寶最近提交給美國證券交易委員會(美國證券交易委員會)的文件，ELO共同養老保險公司在第一季度將其持有的百時美施貴寶(紐約證券交易所代碼：BMY-GET評級)的股票增持了4.8%。該公司持有這家生物製藥公司174,571股股票，在此期間又購買了8,030股。在最近一次報告期結束時，ELO共同養老金保險公司在百時美施貴寶持有的股份價值12,749,000美元。
A number of other hedge funds also recently bought and sold shares of the business. Norges Bank bought a new stake in Bristol-Myers Squibb during the 4th quarter valued at approximately $1,413,962,000. California Public Employees Retirement System boosted its position in Bristol-Myers Squibb by 59.0% during the 1st quarter. California Public Employees Retirement System now owns 11,771,544 shares of the biopharmaceutical company's stock valued at $859,676,000 after acquiring an additional 4,367,193 shares in the last quarter. Primecap Management Co. CA boosted its position in Bristol-Myers Squibb by 16.9% during the 4th quarter. Primecap Management Co. CA now owns 22,114,455 shares of the biopharmaceutical company's stock valued at $1,378,836,000 after acquiring an additional 3,195,680 shares in the last quarter. Pzena Investment Management LLC boosted its position in Bristol-Myers Squibb by 213.7% during the 1st quarter. Pzena Investment Management LLC now owns 3,625,787 shares of the biopharmaceutical company's stock valued at $264,791,000 after acquiring an additional 2,470,079 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in Bristol-Myers Squibb by 17.0% during the 4th quarter. Deutsche Bank AG now owns 15,372,985 shares of the biopharmaceutical company's stock valued at $958,504,000 after acquiring an additional 2,232,347 shares in the last quarter. Hedge funds and other institutional investors own 73.07% of the company's stock.
其他一些對衝基金最近也買入和賣出了該公司的股票。挪威銀行在第四季度購買了百時美施貴寶的新股份，價值約1,413,962,000美元。加州公共僱員退休制度在第一季度將其在百時美施貴寶的頭寸增加了59.0%。加州公共僱員退休系統現在擁有11,771,544股這家生物製藥公司的股票，價值859,676,000美元，在上個季度額外購買了4,367,193股。PrimeCap Management Co.CA在第四季度將其在百時美施貴寶(Bristol-Myers Squibb)的頭寸增加了16.9%。PrimeCap Management Co.CA現在擁有這家生物製藥公司22,114,455股股票，價值1,378,836,000美元，上個季度又購買了3,195,680股。Pzena Investment Management LLC在第一季度將其在百時美施貴寶的頭寸提高了213.7%。Pzena Investment Management LLC現在擁有這家生物製藥公司3,625,787股股票，價值264,791,000美元，上個季度又收購了2,470,079股。最後，德意志銀行(Deutsche Bank AG)在第四季度將其在百時美施貴寶的頭寸提高了17.0%。德意志銀行(Deutsche Bank AG)目前持有這家生物製藥公司15,372,985股股票，價值958,504,000美元，上個季度又收購了2,232,347股。對衝基金和其他機構投資者持有該公司73.07%的股票。
Bristol-Myers Squibb Stock Down 0.3 %
百時美施貴寶股價下跌0.3%
BMY stock traded down $0.26 during midday trading on Thursday, hitting $74.60. The company's stock had a trading volume of 221,056 shares, compared to its average volume of 9,103,090. The company has a market cap of $159.29 billion, a PE ratio of 24.87, a P/E/G ratio of 1.59 and a beta of 0.40. Bristol-Myers Squibb has a 12 month low of $53.22 and a 12 month high of $80.59. The company has a current ratio of 1.44, a quick ratio of 1.34 and a debt-to-equity ratio of 1.14. The firm's 50-day moving average is $74.94 and its 200-day moving average is $72.99.
週四午盤，BMY股價下跌0.26美元，觸及74.60美元。該公司股票的成交量為221,056股，而其平均成交量為9,103,090股。該公司市值為1,592.9億美元，市盈率為24.87倍，市盈率為1.59倍，貝塔係數為0.40。百時美施貴寶的12個月低點為53.22美元，12個月高位為80.59美元。該公司的流動比率為1.44，速動比率為1.34，債務權益比率為1.14。該公司的50日移動均線切入位在74.94美元，200日移動均線切入位在72.99美元。
Bristol-Myers Squibb Announces Dividend
百時美施貴寶宣佈分紅
The business also recently announced a quarterly dividend, which was paid on Monday, August 1st. Shareholders of record on Friday, July 1st were paid a dividend of $0.54 per share. The ex-dividend date of this dividend was Thursday, June 30th. This represents a $2.16 dividend on an annualized basis and a yield of 2.90%. Bristol-Myers Squibb's dividend payout ratio is presently 71.76%.
該公司最近還宣佈了季度股息，股息於8月1日(星期一)支付。7月1日(星期五)登記在冊的股東獲得了每股0.54美元的股息。本次股息除息日期為6月30日星期四。這意味着年化股息為2.16美元，收益率為2.90%。百時美施貴寶目前的股息支付率為71.76%。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Several analysts have weighed in on BMY shares. Guggenheim lifted their price objective on Bristol-Myers Squibb from $72.00 to $80.00 in a research report on Monday, May 2nd. Raymond James cut Bristol-Myers Squibb from an "outperform" rating to a "market perform" rating in a research report on Friday, June 3rd. They noted that the move was a valuation call. UBS Group boosted their price target on Bristol-Myers Squibb to $73.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 27th. Truist Financial boosted their price target on Bristol-Myers Squibb from $76.00 to $81.00 in a research report on Monday, May 2nd. Finally, JPMorgan Chase & Co. boosted their price target on Bristol-Myers Squibb from $80.00 to $85.00 in a research report on Thursday, July 28th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of "Moderate Buy" and a consensus target price of $75.57.
幾位分析師對BMY的股票進行了分析。在5月2日週一的一份研究報告中，古根海姆將百時美施貴寶的目標價從72.00美元上調至80.00美元。雷蒙德·詹姆斯在6月3日星期五的一份研究報告中將百時美施貴寶的評級從“跑贏大盤”下調至“市場表現”。他們指出，此舉是一次估值預測。瑞銀集團在7月27日週三的一份研究報告中將百時美施貴寶的目標價上調至73.00美元，並給予該股“跑贏大盤”的評級。在5月2日星期一的一份研究報告中，Truist Financial將百時美施貴寶的目標價從76.00美元上調至81.00美元。最後，摩根大通在7月28日星期四的一份研究報告中將百時美施貴寶的目標價從80.00美元上調至85.00美元。一名分析師對該股的評級為賣出，四名分析師給予持有評級，七名分析師給予買入評級，一名分析師給予該股強烈買入評級。根據MarketBeat.com的數據，百時美施貴寶目前的共識評級為“中等買入”，共識目標價為75.57美元。
Insider Buying and Selling at Bristol-Myers Squibb
百時美施貴寶的內幕買賣
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 65,000 shares of the business's stock in a transaction on Monday, June 6th. The shares were sold at an average price of $74.89, for a total transaction of $4,867,850.00. Following the completion of the sale, the executive vice president now directly owns 308,627 shares in the company, valued at approximately $23,113,076.03. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Giovanni Caforio sold 30,000 shares of the company's stock in a transaction on Monday, June 13th. The stock was sold at an average price of $74.04, for a total value of $2,221,200.00. Following the completion of the sale, the chief executive officer now directly owns 551,104 shares in the company, valued at approximately $40,803,740.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sandra Leung sold 65,000 shares of the company's stock in a transaction on Monday, June 6th. The stock was sold at an average price of $74.89, for a total value of $4,867,850.00. Following the completion of the sale, the executive vice president now owns 308,627 shares of the company's stock, valued at $23,113,076.03. The disclosure for this sale can be found here. Company insiders own 0.09% of the company's stock.
在百時美施貴寶的其他新聞中，執行副總裁桑德拉·樑在6月6日星期一的一筆交易中出售了該公司6.5萬股股票。這些股票的平均價格為74.89美元，總成交金額為4,867,850.00美元。出售完成後，執行副總裁總裁現在直接持有該公司308,627股股份，價值約23,113,076.03美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過這個鏈接獲得。在其他新聞方面，首席執行官喬瓦尼·卡福裏奧在6月13日星期一的一次交易中出售了30,000股公司股票。這隻股票的平均售價為74.04美元，總價值為2221,200.00美元。出售完成後，首席執行官現在直接擁有公司551,104股，價值約40,803,740.16美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，這份文件可以在美國證券交易委員會的網站上找到。此外，執行副總裁樑淑儀在6月6日星期一的一筆交易中出售了6.5萬股該公司的股票。這隻股票的平均售價為74.89美元，總價值為4867,850.00美元。出售完成後，執行副總裁總裁現在持有該公司308,627股股票，價值23,113,076.03美元。此次拍賣的披露信息可在此處找到。公司內部人士持有該公司0.09%的股份。
Bristol-Myers Squibb Company Profile
百時美施貴寶公司簡介
(Get Rating)
(獲取評級)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
百時美施貴寶公司在全球發現、開發、許可、製造和營銷生物製藥產品。它提供血液學、腫瘤學、心血管學、免疫學、纖維化、神經科學和新冠肺炎疾病的產品。該公司的產品包括治療多發性骨髓瘤的口服免疫調節藥物Revlimid；用於降低NVAF中風/系統性栓塞風險和治療DVT/PE的口服抑制劑Eiquis；用於抗癌適應症的Opdivo；用於多發性骨髓瘤患者的Pomalyst/Imnovid；以及用於成人活動期RA和牛皮癬關節炎的Orencia。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 3 Stable Growth Stocks for Bumpy Times
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- 免費獲取StockNews.com關於百時美施貴寶(BMY)的研究報告
- 找到並獲利於52周低點的股票交易
- 迪士尼(NYSE：DIS)的股票剛剛給了投資者一個巨大的信號
- 清潔能源法案通過後，太陽能股大放異彩
- 顛簸時代的3只穩定成長股
- 大型和小型石油和天然氣類股盈利後反彈
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
接受百時美施貴寶日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對百時美施貴寶及相關公司評級的每日摘要。
譯文內容由第三人軟體翻譯。